trial

6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)

NCTId NCT01098110
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 532 (actual)
Sponsored by Organon and Co
Primary completion 2014-04-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
532 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-05-25
Primary completion
2014-04-14
Eligibility
ALL · 20 Years · 64 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Part — primary completion2014-04-14

Facts & assertions

4 sourced
Enrollment
532
Phase
PHASE3
Primary Completion Date
2014-04-14
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication